EUROPE RESEARCH ROUNDUP-Greencore, UCB, Unilever July 26 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Greencore, UCB, and Unilever, on Friday. HIGHLIGHTS * Greencore GNC.L : HSBC raises target price to 190p from 160p * Lonza Group AG LONN.S : JP Morgan raises target price to CHF 645 from CHF 600 * Sartorius Stedim Biotech STDM.PA : HSBC cuts target price to EUR 310 from EUR 360 * UCB SA UCB.BR : TD Cowen raises target price to E

Swiss stocks - Factors to watch on July 26 July 26 - Here are some of the main factors that may affect Swiss stocks on Friday: HOLCIM HOLN.S Reports Q2 results slightly ahead of forecasts. COMPANY STATEMENTS AMS OSRAM AMS.S Second quarter earnings release due. FORBO HOLDING FORN.S Confirms spring outlook for full year 2024. VONTOBEL VONN.S Half-year earnings release due.

UPDATE 2-European shares fall as earnings deluge disappoints STOXX 600 down 0.7% Universal Music Group slumps as streaming growth disappoints Kering down after weak H2 forecast Besi tumbles as Q3 outlook disappoints Unilever gains after H1 profit beat Updated at 1600 GMT By Pranav Kashyap and Shashwat Chauhan July 25 (Reuters) - European shares closed lower on Thursday as a slate of downbeat earnings reports in several sectors including tech and luxury weighed, while a global run for safe haven

BUZZ-Swiss pharma firm Lonza hits 1-year high on earnings beat Updates share move, adds milestone ** Shares in Lonza LONN.S jump 8% to their highest level in a year after the Swiss contract drug manufacturer's H1 core earnings fell less than expected by the market ** The stock tops the broad Swiss blue-chip index .SSMI , which was down 0.5% by 0717

BUZZ-Swiss pharma firm Lonza seen up on smaller-than-expected earnings drop ** Shares in Swiss contract drug manufacturer Lonza LONN.S are seen rising 3.5% in the Julius Baer premarket indications after its H1 core earnings fell less than expected by the market ** H1 adjusted EBITDA fell to 893 million Swiss francs ($976.4 million), vs 802 million

UPDATE 3-Swiss pharma firm Lonza's profit falls less than feared, shares rise Rewrites with details on shares, adds analyst comment, details on Biologics unit, background; paragraphs 1-4 By Isabel Demetz and Andrey Sychev July 25 (Reuters) - Swiss contract drug manufacturer Lonza LONN.S reported a smaller-than-expected decline in first-half profit on Thursday, as a strong performance in its core Biologics unit partly offset weak demand for capsules.

Swiss pharma supplier Lonza reports lower half-year results July 25 (Reuters) - Swiss contract drug manufacturer Lonza LONN.S reported a drop in its half year profit, hurt by lacklustre demand in its capsules and health ingredients businesses, but beat market estimates, it said on Thursday. It reported an adjusted core earnings before interest, taxes, depreciation and amortization (EBITDA) of 893 million Swiss francs ($976.4 million), compared to 922 million Swiss francs a year earlier.

Swiss stocks - Factors to watch on July 25 ZURICH/GDANSK, July 25(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: COMPANY STATEMENTS DORMAKABA DOKA.S Dormakaba expands production in India. LEONTEQ LEON.S Leonteq says outlook for 2024 is reaffirmed. BUCHER INDUSTRIES AG BUCN.S Bucher Industries says group expects lower sales in 2024. BACHEM HOLDING AG BANB.S Half-year results due.

BRIEF-Lonza Announces New Group Chief Executive Officer Wolfgang Wienand July 1 (Reuters) - LONZA GROUP AG LONN.S : WELCOMES NEW GROUP CHIEF EXECUTIVE OFFICER WOLFGANG WIENAND ALBERT M. BAEHNY WILL RETIRE FROM LONZA GROUP FOLLOWING A TRANSITION PERIOD WOLFGANG WIENAND COMMENCES HIS TENURE AS CHIEF EXECUTIVE OFFICER OF LONZA GROUP Source text for Ei

EUROPE RESEARCH ROUNDUP-ABB, Klepierre, Ryanair June 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including ABB, Klepierre and Ryanair, on Thursday. HIGHLIGHTS * ABB Ltd ABBN.S : Citigroup cuts to neutral from buy * ASM International NV ASMI.AS : Morgan Stanley raises to overweight from equal weight * Deutsche Lufthansa AG LHAG.DE : Stifel cuts to hold from buy * Klepierre LOIM.PA : HSBC raises to buy from hold * Ryanair RYA.I : UBS cu

EUROPE RESEARCH ROUNDUP-AB Dynamics, Etteplan, Wise June 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AB Dynamics, Etteplan and Wise, on Friday. HIGHLIGHTS * AB Dynamics Plc ABDP.L : Berenberg re-initiates coverage With Buy rating; PT 2,620p * Crest Nicholson CRST.L : Barclays cuts target price to 230p from 258p * Etteplan Oyj ETTE.HE : Evli Research raises to buy from hold * Halma HLMA.L : Barclays raises target price to 284

EUROPE RESEARCH ROUNDUP-Asmi, Beiersdorf, SSE June 7 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Asmi, Beiersdorf and SSE, on Friday. HIGHLIGHTS * Arcadis NV ARDS.AS : KBC Securities raises to accumulate from buy * Asmi ASMI.AS : Berenberg raises target price to EUR 720 from EUR 640 * Beiersdorf BEIG.DE : HSBC raises target price to EUR 158 from EUR 152 * Nibe Industrier AB NIBEB.ST : HSBC cuts to hold from buy * SSE SSE.L : HS

CORRECTED-EUROPE RESEARCH ROUNDUP-Asmi, Beiersdorf, SSE Corrects Greenyard NV entry to say KBC Securities raises target price to EUR 9.5 from EUR 8.5 (not 6.30) and Arcadis NV entry to say KBC Securities cuts (not raises) to 'accumulate' from 'buy'; raises target price to EUR 66 from EUR 61 (not 61.7 June 7 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Asmi, Beiersdorf and SSE, on Friday.

UPDATE 1-Swiss pharma supplier Lonza reports softer Q1 but confirms outlook Adds outlook in paragraph 1, info about Biosecure Act in paragraph 5-6, CFO quote in paragraph 7 By Chiara Holzhaeuser and Tristan Veyet May 14 (Reuters) - Swiss pharmaceutical supplier Lonza LONN.S reported a "softer Q1" on Tuesday, while confirming its 2024 outlook, saying its lacklustre performance was mainly due to the phasing of commercial batches and a weaker start at its bioscience business.

Swiss pharma supplier Lonza flags signs of recovery in biotech funding May 14 (Reuters) - Swiss pharmaceutical supplier Lonza LONN.S confirmed its 2024 outlook on Tuesday, flagging early signs of recovery in biotech funding even as clinical demand in its biologics division remained soft in the first quarter. It said commercial performance was positive across its biologics, small molecules, and cell & gene businesses in the quarter, while development in its capsules & health ingredients unit was

BRIEF-Lonza Group Confirms 2024 Outlook May 14 (Reuters) - LONZA GROUP AG LONN.S : PERFORMANCE IN LINE WITH EXPECTATIONS FOR FULL-YEAR 2024 H2 SALES EXPECTED TO BE SOLID CONFIRMS OUTLOOK 2024 Source text for Eikon: ID:nSN6xhSvm Further company coverage: LONN.S (Gdansk Newsroom)

Swiss stocks - Factors to watch on May 14 ZURICH/BERLIN, May 14 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Tuesday: UBS UBSG.S UBS CEO Sergio Ermotti warned on Monday that any delay to the integration of its technology and data with those of former rival Credit Suisse would erode planned cost savings, as he vowed to see the process through and stay on until 2027. GLENCORE GLEN.L Australia's Queensland state will decide this month whether to give Glencore a key

Swiss stocks - Factors to watch on May 13 ZURICH/BERLIN, May 13(Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: NESTLE NESN.S Media/Bloomberg - PAI to delay exit from 10 million dollar ice cream joint venture. KL 1 Together with the German aviation firm Lilium 5KD.F , the company will set up new sites in France in a combined investment of 700 million euros.

EUROPE RESEARCH ROUNDUP-Adecco Group, Centrica, UBS May 8 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adecco Group, Centrica and UBS, on Wednesday. HIGHLIGHTS * Adecco Group AG ADEN.S : RBC raises to outperform from sector perform * Centrica CNA.L : UBS raises to buy from neutral * Direct Line Insurance DLGD.L : Morgan Stanley resumes coverage with equal-weight rating * Lindt & Spruengli LISN.S : Barclays raises to equal weight

Swiss stocks - Factors to watch on May 8 ZURICH/BERLIN, May 8(Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: COMPANY STATEMENTS * Talenthouse THAGN.S - Postponement Of Publication Of The Annual Report 2023 Until 31 May 2024 * EDAG Engineering Group ED4.DE - Harald Keller Appointed CEO As Of July 01, 2024 * Garrett Motion G02.F - Upsizing And Pricing Of Private Offering Of $800 Million Of Senior Notes Due 2032 ANNUAL GENERAL MEETINGS ALCON AG ALCC.S - 0.24